Investment Type: Venture Capital
Mentions in press and media 11
Date | Title | Description | Source |
15.12.2016 | Oncorus Announces Additional Series A Financing Support From... | Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of... | citybizlis... |
20.05.2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45... | finsmes.co... |
20.05.2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financi... | eFFECTOR Therapeutics Raises $45 Million in Series A Financing Company to Focus on Small Molecule S... | fiercebiot... |
26.02.2013 | DecImmune Therapeutics Secures $2.25M | CAMBRIDGE, MA, DecImmune Therapeutics announced today that it has completed a $2.25 million equity... | vcnewsdail... |
26.02.2013 | DecImmune Therapeutics Completes $2.25M Equity Financing | DecImmune Therapeutics, a Cambridge, MA-based company that develops novel peptides and antibodies fo... | finsmes.co... |
21.08.2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begi... | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B ... | medcitynew... |
15.11.2011 | Hyperglycemia drug gets positive results in clinical trial | GLP-1 analogues that have been approved by the U.S. Food and Drug Administration need to be given at... | medcitynew... |
11.10.2011 | Cleave Biosciences Raises $42M in Series A Financing | Cleave Biosciences, a Burlingame, California-based newly established biopharmaceutical company disco... | finsmes.co... |
07.01.2009 | Intradigm closes $21.4M for cancer therapeutics | Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bring... | venturebea... |
- | Type 2 diabetes drug with goal of 24/7 glycemic control begi... | A biotechnology company developing a long-acting drug for hyperglycemia associated with type 2 diabe... | medcitynew... |
Show more